Disc Medicine, Inc. IRON R2K
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -117.7% CAGR over 5 years.
- Trading 26.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IRON Disc Medicine, Inc. R2K | 69.57 | - | $2.66B | - | -27.03% | -35.83% | - | -117.71% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.95M | 61.41M | 67.70M | 66.97M | 69.52M |
| Operating Income | -9.63M | -6.67M | -7.95M | -16.49M | -16.32M | -18.45M | -9.96M | -12.02M | -10.48M | -25.12M | -17.33M | -18.96M | -31.46M | -30.85M | - | -39.95M | -61.41M | -67.70M | -66.97M | -69.52M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.05M | -54.20M | -61.22M | -59.47M | -62.52M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 897.00K | 910.00K | 917.00K | 883.00K | 844.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.97M | -55.20M | -62.22M | -60.44M | -63.45M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 119.00K | 52.00K | 102.00K | 88.00K | 51.00K |
| Net Income | -9.75M | -6.77M | -10.00M | -19.05M | -16.45M | -18.55M | -9.85M | -9.58M | -16.15M | -22.78M | -15.95M | -14.12M | -26.95M | -26.35M | - | -34.09M | -55.25M | -62.32M | -60.53M | -63.50M |
| Diluted EPS | - | - | - | - | -0.38 | -0.43 | -10.67 | -10.14 | -16.82 | -1.20 | -0.74 | -0.58 | -1.09 | -1.03 | -0.89 | -1.02 | -1.58 | -1.77 | - | -1.65 |
| R&D Expense | 8.22M | 5.53M | 6.73M | 11.79M | 10.84M | 13.46M | 7.82M | 7.71M | 7.89M | 20.18M | 12.10M | 14.42M | 23.70M | 23.48M | 24.68M | 27.76M | 46.32M | 50.33M | - | 45.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 47.48M | 91.12M | 129.72M | 236.02M |
| Operating Income | -34.04M | - | -47.48M | -91.12M | -129.72M | -236.02M |
| EBITDA | - | - | -47.39M | -76.23M | -108.27M | -207.94M |
| Interest Expense | - | 2.16M | - | 0 | 572.00K | 3.61M |
| Pretax Income | - | - | -46.83M | -76.33M | -109.00M | -211.82M |
| Tax Provision | - | - | 0 | 99.00K | 355.00K | 361.00K |
| Net Income | -40.84M | - | -46.83M | -76.43M | -109.36M | -212.18M |
| Diluted EPS | - | -44.90 | -45.05 | -3.42 | -3.96 | - |
| R&D Expense | 28.17M | 25.17M | 33.44M | 69.26M | 96.67M | 170.64M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -117.71% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +49.04% |
| 6 Months: | -24.81% |
| 3 Months: | +4.43% |
| 1 Month: | +5.46% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 8.32M | - | 200.21M | 368.00M | 496.77M | 806.88M |
| Current Assets | - | - | - | 198.49M | 365.66M | 493.62M | 803.90M |
| Cash & Equivalents | - | 4.50M | - | 194.61M | 360.38M | 192.43M | 91.14M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 30.18M | - | 23.61M | 22.88M | 53.19M | 67.05M |
| Current Liabilities | - | 24.88M | - | 22.58M | 21.44M | 23.32M | 36.64M |
| Long Term Debt | - | 14.00M | 404.00K | - | - | 28.32M | 29.16M |
| Total Debt | - | - | - | 1.33M | 2.10M | 30.00M | 31.02M |
| Total Equity | -10.43M | -28.81M | - | 176.60M | 345.12M | 443.59M | 739.83M |
| Shares Outstanding | - | - | - | 17.40M | 24.36M | 29.87M | 37.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.71M | - | -42.25M | -73.46M | -93.93M | -180.39M |
| Investing Cash Flow | -22.00K | - | -151.00K | -89.00K | -292.33M | -394.30M |
| Financing Cash Flow | 34.25M | - | 148.98M | 239.38M | 218.31M | 473.41M |
| Capital Expenditure | -22.00K | - | -151.00K | -89.00K | -505.00K | -933.00K |
| Free Cash Flow | -32.73M | - | -42.40M | -73.55M | -94.43M | -181.33M |
| Net Change in Cash | - | - | 106.58M | 165.83M | -167.94M | -101.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 141.8% | - | -26.5% | -22.1% | -24.7% | -28.7% |
| ROCE % | 205.6% | - | -26.7% | -26.3% | -27.4% | -30.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.63% | 5.59M | $388.68M |
| 2 | RA Capital Management, L.P. | 6.41% | 2.45M | $170.46M |
| 3 | Blackrock Inc. | 5.95% | 2.27M | $158.19M |
| 4 | Wellington Management Group, LLP | 4.54% | 1.74M | $120.73M |
| 5 | State Street Corporation | 4.45% | 1.70M | $118.15M |
| 6 | Price (T.Rowe) Associates Inc | 4.06% | 1.55M | $107.79M |
| 7 | Atlas Venture Life Science Advisors, LLC | 3.96% | 1.51M | $105.32M |
| 8 | Vanguard Capital Management LLC | 3.60% | 1.38M | $95.69M |
| 9 | JPMORGAN CHASE & CO | 3.59% | 1.37M | $95.41M |
| 10 | Frazier Life Sciences Management, L.P. | 3.55% | 1.35M | $94.26M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IRON